Physician profile
Anna Elyse Harden
NPI 1265190979
$1,105.05
in general payments reported to CMS, 2019-2025
14 companies · $552 in 2025
The $552 reported for 2025 was more than what a typical Physician Assistant provider received nationally (typical 2025 total: $183).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2024: $553 · 2025: $552.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,105.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,105.05 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Lilly USA, LLC | $302.93 | 2024-2025 | Zepbound, Mounjaro, Jardiance |
| Novo Nordisk INC | $242.17 | 2024-2025 | Ozempic, Rybelsus, Wegovy |
| Abbvie INC. | $111.15 | 2024-2025 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $102.02 | 2024-2025 | Jardiance, Synjardy |
| Pfizer INC. | $57.13 | 2024 | |
| Otsuka America Pharmaceutical, INC. | $49.73 | 2025 | Rexulti |
| Bayer Healthcare Pharmaceuticals INC. | $49.61 | 2024-2025 | |
| Boston Scientific Corporation | $48.84 | 2024 | Wavewriter Alpha Prime 16 |
| Merck Sharp & Dohme LLC | $31.90 | 2024-2025 | Capvaxive, Gardasil 9, Gardasil |
| Astrazeneca Pharmaceuticals LP | $28.13 | 2024 | Airsupra |
| Viiv Healthcare Company | $24.38 | 2025 | Dovato |
| Janssen Pharmaceuticals, INC | $20.13 | 2024 | Spravato |
| Astellas Pharma US INC | $18.88 | 2025 | Veozah |
| E.R. Squibb & Sons, L.L.C. | $18.05 | 2025 | Cobenfy |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Anna Harden listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.